Press "Enter" to skip to content

New patent expiration for Pf Prism drug XELJANZ

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Pf Prism drug XELJANZ

Annual Drug Patent Expirations for XELJANZ
Annual Drug Patent Expirations for XELJANZ

Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. It is available from two suppliers. There are nine patents protecting this drug and two Paragraph IV challenges.

XELJANZ drug price trends.

Drug patent litigation for XELJANZ.

This drug has one hundred and eigthy-four patent family members in fifty-nine countries.

The generic ingredient in XELJANZ is tofacitinib citrate. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Pf Prism drug XELJANZ
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions